Related Experiment Video

Updated: Sep 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

[Use of beta-blockers for treatment of cardiac failure]

C Rodríguez Moreno1, C Durán Parrondo, E G Donado Budiño

  • 1Servicio de Farmacología Clínica, Hospital Clínico Universitario, Vidán s/n, 15706 Santiago de Compostela.

Anales De Medicina Interna (Madrid, Spain : 1984)
|September 13, 2002
PubMed

Insights

Betablockers significantly improve survival and heart function in chronic systolic heart failure. Careful dose titration is crucial to avoid worsening symptoms and manage potential complications in heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Betablocker therapy is a cornerstone in managing chronic systolic heart failure, supported by extensive research over two decades.
  • Established neurohormonal mechanisms underpin the rationale for betablocker use in heart failure.

Purpose:

  • To summarize the established benefits of betablockers in chronic systolic heart failure.
  • To address the potential risks and challenges associated with initiating betablocker therapy.
  • To highlight ongoing questions regarding betablocker use in severe heart failure and specific patient populations.

Summary:

  • Recent clinical trials demonstrate that betablockers unequivocally improve survival rates by 35%, reduce hospitalizations, and enhance left ventricular function in patients with chronic systolic heart failure.
  • Initiating betablocker therapy requires caution, starting with very low doses and titrating slowly to mitigate the risk of exacerbating heart failure symptoms.
  • Key areas requiring further investigation include the role of betablockers in disease progression, optimal agent selection, and their application in critically ill or elderly heart failure patients.

Impact:

  • Provides a concise overview of betablocker efficacy and safety considerations in heart failure management.
  • Identifies critical knowledge gaps and future research directions for optimizing betablocker therapy in diverse heart failure scenarios.
  • Supports clinical decision-making by balancing proven benefits against potential adverse effects and treatment complexities.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...